[Evaluation of the benefits of sodium 2-mercaptoethane sulfonate (MESNA) therapy for children undergoing high-dose chemotherapy].
Preventive effects of hemorrhagic cystitis by the use of sodium 2-mercaptoethane sulfonate (MESNA) was evaluated in 40 children undergoing peripheral blood stem cell autografts (PBSCT) after marrow-ablative chemotherapy which included high-dose cyclophosphamide (CY, 50mg/kg x 2). Fifteen patients received MESNA (group A) and 25 did not (group B), and all received concomitant hyperhydration (3,000ml/m2/day). No renal dysfunction or toxicity attributed to the use of MESNA was observed in either group of patients. Transient hemorrhagic cystitis developed in one of the 15 group A (6.7%) and 3 of 25 (12.0%) group B patients but there was no statistical significance. Although the results may suggest that MESNA is a controversial agent in preventing hemorrhagic cystitis caused by CY when hyperhydration protocol is used, further observation with a larger number of patients is required to establish a firm conclusion.
Sato
J
J
Department of Pediatrics, Tokushima University.
Takaue
Y
Y
Saito
S
S
Okamoto
Y
Y
Hirao
A
A
Shimizu
T
T
Abe
T
T
Watanabe
T
T
Kawano
Y
Y
Ninomiya
T
T
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007938:Leukemia / Q000628:therapy; D008297:Male; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use*; D033581:Stem Cell Transplantation
D003520:Cyclophosphamide; D015080:Mesna